Main menu

Using nanopore sequencing to ensure the quality of mRNA vaccines


Abstract

Billions of mRNA vaccine doses have been manufactured during the COVID-19 pandemic. The removal of contaminating RNAs and inclusion of modified nucleotides reduces the innate immune response and improves the translation and performance of mRNA vaccines. Here we show how nanopore sequencing can analyse the manufacture and quality of mRNA vaccines. Nanopore sequencing enables quantitative analysis of mRNA vaccine sequences, length, and purity, including detection of off-target RNA impurities. Direct RNA sequencing can also measure the incorporation of modified nucleotides and 5’ capping of mRNA vaccines. Together, this shows how nanopore sequencing can inform best manufacturing practices, routinely monitor batch quality, and provide a detailed characterisation of the final mRNA vaccine product.

Authors: Tim Mercer

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

ナノポア技術

ナノポアの最新ニュースを購読 リソースと発表文献 Nanopore Communityとは

Oxford Nanoporeについて

ニュース 会社沿革 持続可能性 経営陣 メディアリソース & お問い合わせ先 投資家向け パートナー向け Oxford Nanopore社で働く 現在の募集状況 営業上の情報 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag